COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
Scientists from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) program developed a powerful tool to explore associations between multiple types of omics datasets. The LinkedOmics software collects genomic, transcriptomic and proteomic datasets from
In a study published on April 21, in Cell Reports Medicine, researchers with the National Cancer Institutes’ (NCI) Clinical Proteomics Tumor Analysis Consortium (CPTAC) take a comprehensive look at the root causes of ovarian high-grade serous carcinoma (HGSC). Through integrated proteomic and genomic an
One of the missions of theClinical Proteomic Tumor Analysis Consortium (CPTAC) is to provide proteomic resources to the greater scientific community. So, we have great news to announce! CPTAC has added 150 "fit-for-purpose," multiplexed, mass spectrometry-based proteomic targeted assays to its Assay Portal!
It’s that time again! CPTAC radiology images have been released on the TCIA CPTAC Pathology Portal! Between conference calls and literature searches, take a look at the 38 new radiology and 8 new pathology images added to Portal – all for free!
Finding novel interactions from comprehensive genomics and proteomics (mass spectrometry generated) is made significantly easier with the help of a visual, interactive guide.
NCI announces the launch of the NCI Proteomic Data Commons (PDC)!
New histopathology slides available from CPTAC lung squamous cell carcinoma, lung adenocarcinoma and glioblastoma multiforme studies. 149 images from 28 new cases added in the month of February 2020 are publicly available on the TCIA CPTAC Pathology Portal!
Protein ubiquitylation is best known for its role in degradation, leading molecules to the cell’s recycle bin, but it also has roles in cellular processing and protein interactions. Unfortunately, research using proteomic techniques have been limited due to experimental and technical complications.
The Cancer Imaging Archive (TCIA) houses radiology and histopathology data for the CPTAC Program. There are over 1500 cases and with more than 6000 images…and counting…of 10 cancer types freely available for the public to view. Each case has complementary proteomic data through the Proteomic Data Commons and genomic data through the
After 12 million measurements, new drug targets emerge
The Office of Cancer Clinical Proteomics Research (OCCPR) cares what you think about the Clinical Proteomic Tumor Analysis Consortium (CPTAC) program and all its offerings! Working with Clarivate Analytics to conduct a survey, we wanted to determine the effect of the CPTAC program on the proteogenomic research community. The evaluation provided the NCI with an objective, third-party assessment of CPTAC program implementation.
The addition of 367 new pathology slides and 51 new pathology subjects for lung squamous cell carcinoma is now available on the TCIA CPTAC Pathology Portal. Additional imaging data is also available for 10 cancer types including cutaneous melanoma, clear cell renal cell carcinoma, head & neck squamous cell carcinoma, glioblastoma multiforme, lung adenocarcinoma
Visualizing gene and protein expression from comprehensive genomics and proteomics (mass spectrometry generated) data is beneficial for researchers but often difficult to achieve. Researchers from the Mount Sinai PGDAC team within the CPTAC program have developed a new interactive data tool to query genes and proteins of interest in a visual format.
Using a single-needle biopsy and new technology for tumor diagnosis developed by Baylor College of Medicine and the Broad Institute of MIT and Harvard, researchers have been able to provide a more detailed and wider window into cancer biology, tumor type and the mechanisms of response and resistance to therapy than with conventional approaches.
The Genomic Data Commons (GDC) data release 22 is now available and includes data from the CPTAC Glioblastoma Multiforme Discovery Study.
The Clinical Proteomic Tumor Analysis Consortium (CPTAC), sponsored by the National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research (OCCPR) and managed by The Frederick National Laboratory for Cancer Research (FNLCR), is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteomics, genomics and proteogenomics.
Glioblastoma Multiforme Discovery Study proteomic and phosphoproteomic data previously available only on thte CPTAC Data Portal is now available on the Proteomic Data Commons.
TCIA has released its quarterly update for CPTAC radiology data with 44 new radiology cases! These cases span cutaneous melanoma, glioblastoma multiforme, head & neck squamous cell carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, pancreatic ductal adenocarcinoma and sarcoma tumor tissue types. In addition, the TCIA monthly histopathology report lists the addition of 10 new pathology slides
Antibodies are among the most commonly used tools in the biological sciences - put to work in many experiments to identify and isolate other molecules. NCI’s Antibody Program has developed more than 500 available antibodies that have been designed and optimized, with the vast majority developed as fit-for-purpose reagents.
Proteomic and phosphoproteomic data for the CPTAC Glioblastoma Discovery Study is now available on the CPTAC Data Portal.